| Dr Bonita L Jones, MD | |
|
960 Agard Ave, Benton Harbor, MI 49022-4051 | |
| (269) 927-5162 | |
| (269) 928-5319 |
| Full Name | Dr Bonita L Jones |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 960 Agard Ave, Benton Harbor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629042650 | NPI | - | NPPES |
| 1907923 | Other | MI | CIGNA |
| 1601110521 | Other | MI | BLUE CROSS |
| 4686697 | Medicaid | MI | |
| 01-30395 | Other | MI | PHP |
| P00245388 | Other | MI | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 4301084649 (Michigan) | Primary |
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).
Work groups at Technische Universit-t M-nchen under Prof. Peter Schieberle and at the University of Vienna under Prof. Veronika Somoza studied four different edible fats and oils: Lard, butterfat, rapeseed oil and olive oil.
The U.S. Food and Drug Administration has approved the biologic drug etanercept (brand name Enbrel) to treat chronic, moderate to severe plaque psoriasis in adults.
Scientists at the University of Massachusetts Medical School have shown that diffuse large B-cell lymphoma (DLBCL) may be susceptible to treatment by re-activating the normal aging program in tumor cells so they can no longer divide.
A team of Swedish researchers finds that early cardiopulmonary resuscitation more than doubles the chance of survival for patients suffering out-of-hospital cardiac arrest. The percentage of patients who receive life-saving resuscitation has also increased substantially thanks to so-called SMS Lifesavers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Bonita L Jones, MD 960 Agard Ave, Benton Harbor, MI 49022-4051 Ph: (269) 927-5162 | Dr Bonita L Jones, MD 960 Agard Ave, Benton Harbor, MI 49022-4051 Ph: (269) 927-5162 |
News Archive
Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).
Work groups at Technische Universit-t M-nchen under Prof. Peter Schieberle and at the University of Vienna under Prof. Veronika Somoza studied four different edible fats and oils: Lard, butterfat, rapeseed oil and olive oil.
The U.S. Food and Drug Administration has approved the biologic drug etanercept (brand name Enbrel) to treat chronic, moderate to severe plaque psoriasis in adults.
Scientists at the University of Massachusetts Medical School have shown that diffuse large B-cell lymphoma (DLBCL) may be susceptible to treatment by re-activating the normal aging program in tumor cells so they can no longer divide.
A team of Swedish researchers finds that early cardiopulmonary resuscitation more than doubles the chance of survival for patients suffering out-of-hospital cardiac arrest. The percentage of patients who receive life-saving resuscitation has also increased substantially thanks to so-called SMS Lifesavers.
› Verified 5 days ago
Dr. Dustin James Hall, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 800 M 139, Benton Harbor, MI 49022 Phone: 269-927-5400 |